{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-048558","form_type":"8-K","ticker":"UTHR","cik":"0001082554","company_name":"UNITED THERAPEUTICS Corp","filed_at":"2022-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.666855+00:00","generated_at":"2026-06-26T05:15:35.570756+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CMS expands Tyvaso coverage to include PH-ILD; effective June 5, 2022","bullets":["CMS updated Local Coverage Determination for Tyvaso (treprostinil) to include pulmonary hypertension associated with interstitial lung disease.","Coverage effective June 5, 2022, after a 45-day notice period as announced April 21, 2022.","Tyvaso is a treprostinil inhalation solution marketed by United Therapeutics for pulmonary hypertension."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-048558","json":"https://secwatch.observer/filing/0001104659-22-048558.json","markdown":"https://secwatch.observer/filing/0001104659-22-048558.md","text":"https://secwatch.observer/filing/0001104659-22-048558.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1082554/000110465922048558/0001104659-22-048558-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1082554/000110465922048558/tm2213312d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T05:15:35.570756+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}